For the -month periods ended and our total stock-based compensation expense, which includes reversals of expense for certain forfeited or cancelled awards, was approximately and respectively. We have recorded any income tax benefit related to stock-based compensation in either of the -month periods ended and

 

A summary of the status of our stock options as of and changes during the -month period then ended, is presented below.

 

		T hree Months Ended March 31, 201 9
		Number of Options				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life				Aggregate Intrinsic Value
Outstanding at beginning of period			157,908			$	24.82
Granted			95,250				5.89
Exercised			—				—
Canceled and Forfeited			(5,300	)			8.93
Expired			(350	)			11.00
Outstanding at end of period (in years)			247,508			$	17.90				7.7			$	—
Exercisable at end of period (in years)			84,175			$	34.35				4.8			$	—

 

A summary of the status of our unvested restricted stock as of and changes during the -month period then ended, is presented below.

 

		Three Months Ended March 31, 201 9
		Number of Shares				Weighted Average Grant-Date Fair Value
Unvested at beginning of period			5,000			$	7.42
Granted			15,000				2.75
Vested			(5,000	)			7.42
Forfeited			—				—
Unvested at end of period			15,000			$	2.75

 

As of there was approximately of total unrecognized compensation expense related to unvested stock-based awards, which we expect to recognize over the remaining weighted average vesting term of years.